(Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced preliminary unaudited revenue for the quarter and year ended December 31, ...

Consensus $79.24M. The company said, “Preliminary unaudited revenue for the full year ended December 31, 2024 is expected to be between $79.4 ...

Notably, 79% of all epilepsy GWAS participants were recruited from the U.K. The studies spanned genetic/idiopathic generalized epilepsy (childhood absence epilepsy, juvenile myoclonic epilepsy ...